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Probiotics have beneficial 
metabolic effects in patients 
with type 2 diabetes mellitus: 
a meta‑analysis of randomized 
clinical trials
tícia Kocsis1, Bálint Molnár1, Dávid Németh1, Péter Hegyi1,2, Zsolt Szakács1,3, 
Alexandra Bálint1,4, András Garami1, Alexandra Soós1, Katalin Márta1 & Margit Solymár1*
Probiotics have been reported to have a positive impact on the metabolic control of patients with 
type 2 diabetes. We aimed to systematically evaluate the effects of probiotics on cardiometabolic 
parameters in type 2 diabetes based on randomized controlled studies. MEDLINE, Embase, and 
CENTRAL databases were reviewed to search for randomized controlled trials that examined 
the effects of probiotic supplementation on cardiometabolic parameters in patients with type 2 
diabetes. 32 trials provided results suitable to be included in the analysis. The effects of probiotics 
were calculated for the following parameters: BMI, total cholesterol levels, LDL, triglycerides, 
HDL, CRP, HbA1c levels, fasting plasma glucose, fasting insulin levels, systolic and diastolic blood 
pressure values. Data analysis showed a significant effect of probiotics on reducing total cholesterol, 
triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels, and both systolic and 
diastolic blood pressure values. Supplementation with probiotics increased HDL levels however did 
not have a significant effect on BMI or LDL levels. Our data clearly suggest that probiotics could be 
a supplementary therapeutic approach in type 2 diabetes mellitus patients to improve dyslipidemia 
and to promote better metabolic control. According to our analysis, probiotic supplementation is 
beneficial in type 2 diabetes mellitus.
Type 2 diabetes mellitus is one of the major worldwide unresolved health challenges: it is a major risk factor 
for a number of common, sometimes potentially lethal diseases, such as hypertension, stroke, coronary heart 
 disease1, or kidney failure and  retinopathy2. According to the International Diabetes Federation, the worldwide 
prevalence of diabetes mellitus was 8.8% in 2015, and by 2040 the prevalence of diabetes in adults is predicted to 
rise to 10.4%3. The increasing prevalence of obesity provides ground to the rising prevalence of type 2  diabetes4. 
Even though the main cause of obesity is the imbalanced calorie intake, one intriguing hypothesis links the com-
position of the human gut microbiome to human energy homeostasis; for instance with their ability to promote 
adiposity through manipulation of host genes and metabolism, an altered microbiome can lead to predisposi-
tion to  obesity5. The alteration in the gut microbiota has recently been recognized as a key environmental factor 
resulting in metabolic diseases, such as type 2 diabetes. In fact, the gut microbiota is involved in the maintenance 
of host energy homeostasis and in the stimulation of host immunity through a molecular  crosstalk6.
Although many drugs have been developed to maintain glycemic control and normalize blood glucose levels 
either via enhanced insulin production and utilization, suppressed glucose production and absorption, by block-
ing urine glucose re-absorption and increasing glucose excretion in urine, or the combination of  these7, these 
drugs may cause several adverse effects such as sulphonylureas carry a risk of causing acute severe hypoglycemia; 
lactic acidosis is also a potentially serious adverse effect associated with the use of biguanides; and gastrointestinal 
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adverse effects may occur with the use of  metformin8. Alternatively, the potential role of modifications in the 
gut microbiome had been explored as a new complementary therapeutic  strategy9. Clinical evidence supports 
the hypothesis that the modulation of the gut microbiota by probiotics could be effective in prevention and 
management of  diabetes10,11.
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on 
the host. The healthy human body contains such microbes physiologically; and they can be obtained in forms of 
over-the-counter food supplements as well. Over the last few years, probiotics, especially the lactobacillus species 
were shown to be effective in the therapy of type 2  diabetes12. In type 2 diabetes, gut microbiome is found to be 
different from that in the healthy population. In a human study, the amount of Firmicutes bacteria was lower, 
whereas the number of Bacteroides and Proteobacteria is higher in the gastrointestinal tract of patients with type 
2 diabetes compared to non-diabetic  persons13. According to the  study13, the ratio of Bacteriodes and Firmicutes 
species had positive correlation with decreased insulin resistance, however, causality has not been proven yet. 
Following innovative dietary strategies, it seems possible to maintain euglycemia by normalizing the altered 
microbiome, and to prevent long-term micro- and macrovascular complications of type 2  diabetes9. Although, 
there have been numerous bacterial species investigated in the therapy of type 2 diabetes, no consensus has been 
obtained regarding the effectivity and the most effective species. For instance, an earlier meta-analysis suggested, 
that the intake of certain Lactobacillus species, such as L. fermentum, L. ingluviei and L. acidophilus can lead to 
weight gain, while the ingestion of L. gasseri and L. plantarum might end up in weight loss both in animal and 
human  studies14. Previous meta-analysis in this field were not conducted with assessment of the evidence qual-
ity levels and the number of identified trials that met their inclusion criteria was relatively low (7–12 trials)15–19. 
Two meta-analysis found no significant effects of probiotics on lipid  profile16,19 and two meta-analysis found 
decreased indexes of lipid  profiles17,18. These contradictory reports on the effect of probiotics inspired us to con-
duct an updated meta-analysis to assess the effect of probiotic therapies in diabetes mellitus type 2 exclusively 
from randomized controlled trials.
Materials and methods
Protocol and registration. This meta-analysis was reported according to the recommendation of the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)  guidelines20. Pre-specified proto-
col of this meta-analysis was published in the Prospero Center for Reviews and Dissemination (PROSPERO) 
under the registration number of CRD42019137997.
Search strategy. Meta-analysis was performed using the PICO format: whether an intervention with pro-
biotic supplementation (I) compared with placebo (C) has any effect on metabolic parameters (body mass index 
(BMI), total-cholesterol, low density lipoprotein (LDL), triglycerides (TG), high density lipoprotein (HDL), high 
sensitivity C-reactive protein (hs-CRP), haemoglobin A1c (HbA1c), fasting plasma glucose and insulin levels, 
systolic and diastolic blood pressure (SBP, DBP) (O) in patients with diabetes mellitus type 2 (P). In general, the 
following search terms were used in all databases: diabetes mellitus type 2 AND (probiotic* OR lactobacillus OR 
saccharomyces OR enterococcus OR escherichia coli OR streptococcus OR bifidobacterium) AND random*. 
Trials were identified by searching MEDLINE (via PubMed), EMBASE and CENTRAL databases up to 5th of 
April 2019. No filters or restrictions were applied. We included human trials without any restriction to language 
or year of publication.
Eligibility criteria and study selection. Duplicates were removed by the EndNote software first auto-
matically, then manually. Randomized controlled trials in which probiotics in the form of any pharmaceutical 
formulations or dairy products administered to adult patients with type 2 diabetes were included after title and 
abstract screening. Combination therapy was not an exclusion criterion. Subsequently, full texts of the articles 
were reviewed for inclusion of eligible studies. Two review authors (TK and BM) selected the articles fulfilling 
the inclusion criteria independently, and any disagreement was resolved by consensus.
Data collection. At the end of the screening process, relevant data were independently extracted from stud-
ies by the two review authors and any disagreement was resolved by consensus. Data were extracted into a 
standardized excel sheet form. Data extracted from the papers included: number of participants, dosage, the 
intervention used, study duration and the outcome parameters including BMI changes as primary outcome and 
changes in the total-cholesterol, LDL, TG, HDL, hs-CRP, HbA1C, fasting plasma glucose and insulin levels, SBP 
and DBP as secondary outcomes. The authors of the studies and year of publication were also recorded. Mean 
values for control and intervention groups, along with the measure of dispersion were extracted.
Risk of bias assessment. Two review authors assessed the risk of bias of the studies independently, and 
any disagreement was resolved by consensus. The assessment was performed using the updated version of the 
Cochrane risk-of-bias tool for randomized trials (RoB 2) with the following domains: bias arising from the ran-
domization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias 
in measurement of the outcome, bias in selection of the reported result, and overall  bias21.
Quality of evidence. We used the Grading of Recommendations, Assessment, Development and Evalua-
tion (GRADE) approach to rate the quality of evidence on our primary outcomes.
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Statistical analysis. We calculated weighted mean differences (WMD) with 95% confidence intervals (CI) 
as effect size data based on the difference of before-after values in the intervention and comparator groups. Means 
were compared by assessing the overlap of CIs. Between-study heterogeneity was tested with (a) chi2 statistics 
(where p < 0.1 was considered significant) and (b)  I2 statistics, where 75–100% was considered  considerable22. 
Due to the methodological differences between interventions, we performed all analysis under the random effect 
assumption. To assess small study effect, we used visual inspection of funnel plots and Egger’s test was per-
formed. If p ≥ 0.1, publication bias is unlikely to occur in the sample. We used trial sequential analysis to inves-
tigate if alpha and beta-type errors affect our estimates. All analyses were performed with the Comprehensive 
Meta-analysis software (Biostat, Inc., Engelwood, MJ, USA) and Stata 11 SE (Stata Corp) software.
Results
Characteristics of the included studies. A flow chart of selection for the meta-analysis is shown in 
Fig. 1.
32 eligible studies were included in the meta-analysis12,23–52. Main characteristics of the studies included are 
shown in Table 1. Fifteen studies administered one bacterial species, while the rest of the studies used a com-
bination of more than one strain: seventeen studies administered two to seven bacterial species. In one article, 
the flora of the probiotic yoghurt of the intervention group was enriched with specific strains, however placebo 
yoghurt also contained bacterial  flora12. In three articles, probiotics were co-administered with  chromium35,51, 52, 
in one article with  selenium42, and in one article with vitamin  D43. The duration of intervention ranged from four 
to 34 weeks. Seventeen of the 32 articles were published from Iran, two from Saudi Arabia, two from Ukraine, 
two from Brazil, two from India, and the remaining ones from Malaysia, Denmark, Taiwan, Poland, Sweden, 
Japan, and Greek.
Summary of findings. Data of outcome parameters are summarized in Table 2. The summary of findings 
table provides a synopsis of the analysis (Table 3).
Risk of bias within the individual studies. One study had high risk  overall40. In seven studies, some 
concerns were detected; however, we found no articles with any concern about missing outcome data. The qual-
ity of the included studies is shown in detail in Fig. 2. Generally, the quality of the studies was good, in most 
cases with published pre-study protocols. We found three studies that were single-blind37,51,52, three more studies 
without  blinding26,46,48, all the other articles contained double-blind studies.
Probiotics did not change body mass index. Seventeen studies reported BMI changes. Pooled data 
showed no difference between the probiotic and placebo group. Considerable heterogeneity  (I2: 86.6%, p < 0.001) 
was detected.
Figure 1.  A flow diagram detailing process of study selection for the meta-analysis.
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Country
Total number of 
participants Type of participants Strains used Daily dose
Duration of 
treatment (weeks) Outcomes
Abbasi et al.23 Iran 40
T2DM (for: > 1 year, 
FPG: > 126 mg/dL, 
PPG: > 200 mg/dL, 
microalbuminuria, 
GFR: > 60 mL/min)
L. plantarum 2 × 107 CFU/mL 8 BW, BMI, TC, TG, LDL-C, HDL-C
Asemi et al.24 Iran 54
T2DM 
(FPG: > 126 mg/dL/
PPG: > 200 mg/dL/
HbA1c: > 6, 5%)
L. acidophilus
L. casei
L. rhamnosus
L. bulgaricus
B. brevei
B. longum
Strep. thermophilus
2 × 109 CFU
7 × 109 CFU
1.5 × 109 CFU
2 × 108 CFU
2 × 1010 CFU
7 × 109 CFU
1.5 × 109 CFU
8
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
HbA1c, FPG, Insulin
Bahmani et al.25 Iran 81
T2DM 
(FPG: > 126 mg/dL/
PPG: > 200 mg/dL/
HbA1c: > 6,5%)
L. sporogenes 3 × (40 × 108 CFU) 8 BW, BMI
Bayat et al.26 Iran 80
T2DM 
(FPG: > 126 mg/dL 
and controlled lipid 
profile w/o changing 
the drug instruction)
Not specified, probi-
otic yoghurt Not known 8
TC, TG, LDL-C, 
HDL-C, CRP, HbA1c, 
FPG
Ejtahed et al.12 Iran 60
T2DM (for: > 1 year 
and BMI: < 35 and 
LDL-C: > 2.6 mmol/L 
)
L. acidophilus
B. lactis
L. bulgaricus
Strep. thermophilus
300 × (1.05 × 106 CFU)
300 × (1,19 × 106 CFU)
Not known
Not known
6 TC, TG, LDL-C, HDL-C
Feizzollahzadeh 
et al.27 Iran 40 T2DM L. plantarum 2 × 10
7 CFU 8 TG, LDL-C, HDL-C, CRP, FPG
Firouzi et al.28 Malaysia 136
T2DM (for: > 0.5 year, 
HbA1c: 6.5–12%, 
FPG: < 15 mmol/L, 
BMI: 18.5–40)
L. acidophilus
L. casei
L. lactis
B. bifidum
B. longum
B. infantis
1010 CFU
1010 CFU
1010 CFU
1010 CFU
1010 CFU
1010 CFU
12
BW, BMI, TC, TG, 
LDL, HDL, CRP, 
HbA1c, FPG, Insulin, 
SBP, DBP
Hariri et al.29 Iran 40
T2DM (for: > 1 year, 
FPG: > 126 mg/dL, 
PPG: > 200 mg/dL)
L. plantarum 200 × (2 × 107 CFU) 8 BW, BMI, SBP, DBP
Hove et al.30 Denmark 41 T2DM (for: > 1 year, HbA1c: 6–10%) L. helveticus 300 mL 12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
HbA1c, FPG
Hsieh et al.31 Taiwan 68
T2DM (for: 0.5 years, 
BMI: > 18, HbA1c: 
7–10%)
L. routeri (live)
L. routeri (heat killed)
2 × (2 × 109 CFU)
2 × (1 × 1010 CFU) 12
TC, TG, LDL-C, 
HDL-C, HbA1c, Insu-
lin, SBP, DBP
Khalili et al.32 Iran 40 T2DM (for: > 1 years, BMI: < 35) L. casei 10
8 CFU 8
BW, BMI, HbA1c, 
FPG, Insulin, SBP, 
DBP
Kobyliak et al.33 Ukraine 58 T2DM (BMI: > 25, NAFLD)
Lactococcus, 
Bifidobacterium, 
Propionibacterium, 
Acetobacter
10 × (6 × 1010 CFU)
10 × (1 × 1010 CFU)
10 × (3 × 1010 CFU)
10 × (3 × 106 CFU)
8 TC, TG, LDL-C, HDL-C
Kobyliak et al.34 Ukraine 53
T2DM (for: 0.5 years, 
BMI: > 25, HbA1c: 
6.5–11%, HOMA-
IR: > 2)
Lactococcus, 
Bifidobacterium, 
Propionibacterium, 
Acetobacter
10 × (6 × 1010 CFU)
10 × (1 × 1010 CFU)
10 × (3 × 1010 CFU)
10 × (3 × 106 CFU)
8 BW, BMI, HbA1c, FPG, Inulin
Król et al.35 Poland 20 T2DM (BMI: 35.3 (9.2), HbA1c: > 7.0%)
Saccharomyces 
cerevisiae 5 × 100 μg 8
BMI, TC, TG, LDL-C, 
HDL-C, HbA1c, FPG, 
Insulin
Mafi et al.36 Iran 60
T2DM with diabetic 
nephropathy (Pro-
teinuria: > 0.3 g/day)
L. acidophilus
L. reuteri
L. phermentum
B. bifidum
2 × 109 CFU
2 × 109 CFU
2 × 109 CFU
2 × 109 CFU
12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
HbA1c, FPG, Insulin
Mazloom et al.37 Iran 34
T2DM 
(for: < 15 years, 
FPG: > 126 mg/dL)
L. acidophilus
L. bulgaricus
L, bifidum
L. casei
Not known 6 TC, TG, LDL-C, HDL-C, CRP, FPG
Mobini et al.38 Sweden 44
T2DM 
(for: > 0.5 years, 
waist: > 80 cm [F] 
or > 94 cm [M], 
HbA1c: 6.7–10.4%, 
BMI: 25–45)
L. reuteri
L. reuteri
108 CFU
1010 CFU 12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
HbA1c, FPG, SBP, 
DBP
Mohamadshai et al.39 Iran 44 T2DM (BMI: > 25)
L. bulgaricus
Strep. thermophilus
B. lactis
L. acidophilus
Not known
Not known
300 × (3,7 × 106 CFU)
300 × (3,7 × 106 CFU)
8 BW, BMI, CRP, HbA1c, FPG
Continued
5Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11787  | https://doi.org/10.1038/s41598-020-68440-1
www.nature.com/scientificreports/
Country
Total number of 
participants Type of participants Strains used Daily dose
Duration of 
treatment (weeks) Outcomes
Moroti et al.40 Brazil 20
T2DM 
(TC: > 200 mg/dL, 
TG: > 150 mg/dL, 
FPG: > 110 mg/dL)
L. acidophilus
B. bifidum
200 × (1 × 108 CFU)
200 × (1 × 108 CFU) 4,3 TC, TG, HDL-C, FPG
Ostadrahimi et al.41 Iran 60
T2DM 
(for: < 20 years, 
FPG: > 125 mg/dL)
Strep. thermophiles
L. casei
L. acidophilus
B. lactis
Not known
1,200 × (15 × 106 CFU)
1,200 × (25 × 106 CFU)
1,200 × (8 × 106 CFU)
8 BW, TC, TG, LDL-C, HDL-C, HbA1c, FPG
Raygan et al.42 Iran 54 T2DM w/ 2- or 3-ves-sel CHD
L. acidophilus
L. reuteri
L. fermentum
B. bifidum
2 × 109 CFU/g
2 × 109 CFU/g
2 × 109 CFU/g
2 × 109 CFU/g
12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
FPG, Insulin, SBP, 
DBP
Raygan et al.43 Iran 60 T2DM w/ 2- or 3-ves-sel CHD
L. acidophilus
L. reuteri
L. fermentum
B. bifidum
2 × 109 CFU/g
2 × 109 CFU/g
2 × 109 CFU/g
2 × 109 CFU/g
12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
FPG, Insulin, SBP, 
DBP
Raygan et al.44 Iran 60 T2DM w/ 2- or 3-ves-sel CHD
B. bifidum
L. casei
L. acidophilus,
2 × 109 CFU/g
2 × 109 CFU/g
2 × 109 CFU/g
12
BW, BMI, TC, TG, 
LDL-C, HDL-C, CRP, 
FPG, Insulin, SBP, 
DBP
Sabico et al.45 Saudi-Arabia 78
T2DM (for: < 0.5-
year, w/o complica-
tions, HbA1c: < 7%)
B. bifidum
B. lactis
L. acidophilus
L. brevis
L. casei
L. salivarius
Lactococcus lactis 
W19
Lactococcus lactis 
W58
2 × (2.5 × 109 CFU/g) 12
BW, BMI, TC, TG, 
LDL-C, HDL-C, FPG, 
Insulin, SBP, DBP
Sabico et al.45 Saudi-Arabia 61
T2DM (for: < 0.5-
year, w/o complica-
tions, HbA1c: < 7%)
B. bifidum
B. lactis
L. acidophilus
L. brevis
L. casei
L. salivarius
Lactococcus lactis 
W19
Lactococcus lactis 
W58
2 × (2.5 × 109 CFU/g) 34,13
BMI, TC, TG, LDL-C, 
HDL-C, CRP, FPG, 
Insulin, SBP, DBP
Sato et al.46 Japan 68 T2DM (HbA1c: 6–8%) L. casei 4 × 10
10 CFU 16 BMI, TC, TG, HDL-C, CRP, HbA1c, FPG
Shakeri et al.47 Iran 52
T2DM 
(FPG: > 126 mg/dL/
PPG: > 200 mg/dL/
HbA1c: > 6,5%)
L. sporogenes 3 × (40 × 108 CFU) 8 BW, BMI, TC, TG, LDL-C, HDL-C, FPG,
Sharma et al.48 India 40 T2DM (newly onset) Saccharomyces cerevisiae 9 g 12
BMI, TC, TG, LDL-C, 
HDL-C, HbA1c, FPG, 
SBP, DBP
Sheth et al.49 India 35 T2DM (pre-hyper-tensive)
Lactobacillus
Bifidobacterium
Streptococcus
Not known
Not known
Not known
6.43 HbA1c, FPG
Tajadadi-Ebrahimi 
et al. 2014 Iran 71
T2DM 
(FPG: > 126 mg/dL/
PPG: > 200 mg/dL/
HbA1c: > 6.5%)
L. sporogenes, 3 × (40 × 108 CFU) 8 BW, BMI, CRP, FPG, Insulin
Tonucci et al.50 Brazil 55 T2DM (for: > 1 year, BMI: < 35)
Strep thermophilus
L. acidophilus
B. lactis
Not known
120 × 109 CFU
120 × 109 CFU
6
TC, TG, LDL-C, 
HDL-C, HbA1c, FPG, 
Insulin
Yanni et al.51 Greece 30
T2DM (for: > 1 year, 
BMI: < 31, 
FPG: > 125 mg/dL, 
HbA1c: < 8.5%)
Saccharomyces 
cerevisiae Not known 12
BW, BMI, TC, TG, 
HDL-C, CRP, HbA1c, 
FPG, Insulin, SBP, 
DBP
Table 1.  Characteristics and findings of the studies included in the analysis. T2DM type 2 diabetes mellitus, 
FPG fasting plasma glucose, PPG postprandial plasma glucose, HbA1c glycated hemoglobin, GFR glomerular 
filtration rate, BW body weight, BMI body mass index, TC total cholesterol, TG triglyceride, LDL-C low-
density lipoprotein, HDL-C high-density lipoprotein, CFU colony forming unit, CRP C-reactive protein, 
SBP systolic blood pressure, DBP diastolic blood pressure, L. Lactobacillus, B. Bifidobacterium, Strep. 
Streptococcus, NAFLD non-alcoholic fatty liver disease, CHD coronary heart disease, HOMA-IR Homeostatic 
Model Assessment for Insulin Resistance.
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Probiotics improved plasma lipid profile. Twenty-one studies included data about the effect of probiot-
ics on total-cholesterol level. Pooled data showed a significant effect of probiotics on reducing total-cholesterol 
levels with a mean difference of 10.06 mg/dL (95% CI − 15.94, − 4.18, p = 0.001) with a considerable heterogene-
ity  (I2: 93.2%, p < 0.001). Sub-group analysis according to the length of investigation (i.e. duration of treatment) 
did not reduce the heterogeneity (Fig.  3, short:  I2: 93.2%, p < 0.001; long:  I2: 93.4%, p < 0.001). Short studies 
with 8 weeks treatment or shorter showed significant decrease of total cholesterol level (− 14.56 mg/dL, 95% CI 
− 24.82, − 4.29, p = 0.005), while studies of 12 weeks or longer showed no significant change (p = 0.105).
We found a significant difference between these two sub-groups (p = 0.001). Sub-group analysis according 
to the number of bacterial strains (single or multiple, Fig. 4) did not change heterogeneity, either (multiple:  I2: 
91.5%, p < 0.001, single:  I2: 81.6%, p < 0.001). The beneficial effect of multiple strains probiotics on total choles-
terol was significant (− 11.70 mg/dL, 95% CI − 18.60, − 4.79, p = 0.001), however no difference was observed in 
single bacteria probiotic sub-group (p = 0.611) with significant difference between the two sub-groups (p < 0.001).
If we excluded the six articles where probiotics were co-supplemented with either vitamin D or chromium 
or selenium, and the article where the placebo group also got yoghurt with some bacteria, the heterogeneity did 
not change, nor the direction of the association (Figure S1).
Twenty studies reported data about LDL levels. No significant difference in LDL levels was observed between 
probiotic and placebo users (− 3.77 mg/dL, 95% CI − 8.47, 0.93, p = 0.116) with a considerable heterogeneity  (I2: 
88.6%, p < 0.001). Sub-group analysis according to the length of treatment (Figure S2) did not decrease the het-
erogeneity (short:  I2: 88.9%, p < 0.001, long:  I2: 89.5%, p < 0.001). Pooled studies with 8 weeks treatment period or 
shorter (p = 0.167) and studies of 12 weeks or longer showed no change of total cholesterol level (p = 0.493). We 
found no significant difference between these two groups (p = 0.555). Sub-group analysis according to the number 
of bacteria used (single or multiple, Figure S3 did not change heterogeneity, either (multiple:  I2: 90.6%, p < 0.001, 
single:  I2: 86.0%, p < 0.001). We found no effect of multiple-strain probiotics on total cholesterol (p = 0.139), 
and no difference was observed in single bacterium containing probiotic sub-group (p = 0.985), while there 
was no difference between the two sub-groups (p = 0.119). If we excluded the six articles where probiotics were 
co-supplemented with either vitamin D or chromium or selenium, and the article where the placebo group also 
got yoghurt with some bacteria, heterogeneity did not change, either (Figure S4). However, based on our trial 
sequential analysis, a number of 3,442 observations would be needed to provide sufficient statistical power (vs. 
the 1,090 patients in the current analysis) (Figure S5).
The meta-analysis of twenty-one trials showed a significant reduction of triglyceride by 17.18 mg/dL (95% CI 
− 26.17, − 8.19, p < 0.001). Heterogeneity was not substantial (34%, p = 0.065), sub-group analysis was therefore 
not conducted.
The meta-analysis of twenty-two trials showed a significant increase of HDL by 1.62 mg/dL (95% CI 0.21, 
3.04, p = 0.025).  I2 test (57.4%, p < 0.001) may represent moderate heterogeneity due to the differences between 
the interventions.
Probiotics decreased CRP, HbA1c, fasting plasma glucose, fasting insulin, and blood pressure 
values. The meta-analysis of sixteen trials showed a significant decrease of CRP by 0.43  mg/dL (95% CI 
− 0.80, − 0.07, p = 0.019).  I2 test (64.3%, p < 0.001) represented moderate heterogeneity.
Fourteen studies with reported the effect of probiotics on HbA1c levels. The decrease of HbA1c was slightly 
but significantly lower in the probiotic groups compared to placebo (− 0.33%, 95% CI − 0.53; − 0.13, p = 0.001). 
Heterogeneity was substantial  (I2: 75.9%, p < 0.001).
Twenty-four studies reported data about fasting plasma glucose. Pooled data showed a significant effect of 
probiotics in reducing fasting plasma glucose levels with a mean difference of − 16.52 mg/dL, (95% CI − 23.28; 
− 9.76, p < 0.001) with a substantial heterogeneity  (I2: 66.2%, p < 0.001). Sub-group analysis according to the 
Table 2.  Summary data of outcome parameters. Bold values indicate statistically significant weighted mean 
differences between the intervention and control groups, where p < 0.05. N number of RCTs, WMD weighted 
mean difference, CI confidence interval, BMI body mass index, T-chol total cholesterol, LDL low-density 
lipoprotein, TG triglyceride, HDL high-density lipoprotein, CRP C-reactive protein, HbA1c hemoglobin A1c, 
FPG fasting plasma glucose, SBP systolic blood pressure, DBP diastolic blood pressure.
N WMD CI low CI high p I2 (%) p  (I2)
BMI (kg/m2) 17 − 0.17 − 0.38 0.04 0.114 86.6  < 0.001
T-chol (mg/dL) 21 − 10.06 − 15.94 − 4.18 0.001 93.2  < 0.001
LDL (mg/dL) 20 − 3.77 − 8.47 0.93 0.116 88.6  < 0.001
TG (mg/dL) 21 − 17.18 − 26.17 − 8.19  < 0.001 34.0 0.065
HDL (mg/dL) 22 1.62 0.21 3.04  < 0.001 57.4  < 0.001
CRP (mg/dL) 16 − 0.43 − 0.8 − 0.07 0.019 64.3  < 0.001
HbA1c (%) 14 − 0.33 − 0.53 − 0.13 0.001 75.9  < 0.001
FPG (mg/dL) 24 − 16.52 − 23.28 − 9.76  < 0.001 66.2  < 0.001
Insulin (µIU/mL) 15 − 1.40 − 2.52 − 0.27 0.015 46.8 0.024
SBP (mmHg) 14 − 1.79 − 3.09 − 0.49 0.007 0.0 0.89
DBP (mmHg) 14 − 1.32 − 2.42 − 0.21 0.019 0.0 0.838
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Table 3.  Probiotics consumption compared to control in diabetes mellitus type 2. CI confidence interval. 
a Considerable heterogeneity was detected. B Differences between interventions were substantial. c Unusually 
high confidence interval in two of the studies. d Unusually high confidence interval in one of the studies. 
e Moderate heterogeneity was detected. f Egger’s test was significant.
Certainty assessment No. of patients Effect
Certainty Importance№ of studies Study design Risk of bias Inconsistency Indirectness Imprecision
Other 
considerations Probiotics Control
Absolute 
(95% CI)
Body mass index
17 Randomized trials Not serious Serious
a Very  seriousb Serious c None 498 497
WMD 
0.17 kg/m2 
lower (0.38 
lower to 0.04 
higher)
Very low
Important
Total cholesterol
21 Randomized trials Not serious Very  serious
a Very  seriousb Not serious None 596 600
WMD 
10.06 mg/dL 
lower (15.94 
lower to 4.18 
lower)
Very low
Important
LDL
20 Randomized trials Not serious Serious
a Very  seriousb Not serious None 546 544
WMD 
3.77 mg/dL 
lower (8.47 
lower to 0.93 
higher)
Very low
Important
Triglyceride
21 Randomized trials Not serious Not serious Very  serious
b Not serious None 546 548
WMD 
17.18 mg/dL 
lower (26.17 
lower to 8.19 
lower)
Low
Important
HDL
22 Randomized trials Not serious Not serious Very  serious
b Serious d None 594 598
WMD 
1.62 mg/dL 
higher
(0.21 higher 
to 3.04 
higher)
Very low
Important
CRP
16 Randomized trials Not serious Serious 
e Very  seriousb Serious d None 467 470
WMD 
0.43 mg/l 
lower (0.8 
lower to 0.07 
lower)
Very low
Important
HbA1c
14 Randomized trials Not serious Serious
a Very  seriousb Not serious None 395 372
WMD 0.33% 
lower (0.53 
lower to 0.13 
lower)
Very low
Important
Fasting plasma glucose
24 Randomized trials Not serious SERIOUS
a Very  seriousb Not serious NONE 649 627
WMD 
16.52 mg/dL 
lower (23.28 
lower to 9.76 
lower)
Very low
Important
Fasting insulin
15 Randomized trials Not serious NOT serious Very  serious
b Not serious None 455 451
WMD 1.4 
µIU/mL 
lower (2.52 
lower to 0.27 
lower)
Low
Important
Systolic blood pressure
14 Randomized trials Not serious Not serious Very  serious
b Not serious
Publication 
bias strongly 
suspected f
417 418
WMD 1.79 
Hgmm 
lower (3.09 
lower to 0.49 
lower)
Very low
Important
Diastolic blood pressure
14 Randomized trials Not serious Not serious Very  serious
b Not serious
Publication 
bias strongly 
suspected f
417 418
WMD 1.32 
Hgmm 
lower (2.42 
lower to 0.21 
lower)
Very low
Important
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length of investigation (Fig. 5) did not change the heterogeneity in the long-term treatment sub-group  (I2: 80.6, 
p < 0.001), however it decreased significantly in the short period therapy sub-group  (I2: 25.8%, p = 0.183).
Short studies with 8 weeks or shorter showed significant decrease of fasting plasma glucose level (− 15.35 mg/
dL, 95% CI − 24.83, − 5.87, p = 0.002), and studies of 12 weeks or longer also showed a significant decrease 
(− 18.82 mg/dL, 95% CI − 28.58, − 9.06, p < 0.001). We found no significant difference between these two sub-
groups (p = 0.723). Sub-group analysis according to the number of applied bacteria strains (single or multiple, 
Fig. 6) showed an increased heterogeneity in the single strain sub-group, and there was some minor decrease in 
the multiple strains sub-group (single:  I2: 74.5%, p < 0.001; multiple:  I2: 60.6%, p < 0.001).
The beneficial effect on fasting glucose level was significant both in the multiple strains probiotics subgroup 
(− 19.84 mg/dL, 95% CI − 31.45, − 8.23, p = 0.001) and in the single bacteria probiotic sub-group (− 16.07 mg/
dL, 95% CI − 25.88, − 6.26, p = 0.001) with no significant difference between the two sub-groups (p = 0.892). 
If we excluded the six articles where probiotics were co-supplemented with either vitamin D or chromium or 
selenium, and the article where the placebo group also got yoghurt with some bacteria, the heterogeneity did 
not change, either (Figure S6).
The meta-analysis of fifteen trials showed a significant reduction of fasting insulin levels by 1.40 µIU/mL 
(95% CI − 2.52, − 0.27, p = 0.015). Heterogeneity was not significant (46.8%, p = 0.024), sub-group analysis was 
therefore not conducted.
Fourteen studies reported data about systolic and diastolic blood pressures. The meta-analysis showed a 
significant decrease both in systolic blood pressure (− 1.79 mmHg, 95% CI − 3.09; − 0.49, p = 0.007,  I2: 0.0%, 
p = 0.890) and in diastolic blood pressure (− 1.32 mmHg, 95% CI − 2.42; − 0.21, p = 0.019,  I2: 0.0%, p = 0.838). 
Since heterogeneity was not significant, no sub-group analysis was performed.
Discussion
In the present meta-analysis, we aimed to evaluate the effects of probiotics on BMI and metabolic parameters in 
patients with type 2 diabetes mellitus. Data analysis showed a significant effect of probiotics in reduction of total 
cholesterol, triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels and both systolic and 
diastolic blood pressure values. Supplementation with probiotics increased HDL levels however did not have a 
significant effect on BMI or LDL levels.
Such an evaluation is of high potential importance, as this patient group has especially high risk of cardiovas-
cular diseases. It is crucial to reduce all the modifiable risk factors with efficient and multifactorial therapeutic 
methods and probiotic supplementation could be a complementary approach.
Figure 2.  Risk of bias summary assessment of the included studies.
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High total cholesterol levels, high blood pressure and type 2 diabetes mellitus are major risk factors of car-
diovascular diseases. Reduction of the high total cholesterol and LDL levels in order to reduce the risk of major 
cardiovascular events is  essential53. Every 1 mmol/L increment in total cholesterol levels increases the risk of 
cardiovascular diseases by 20% in women and by 24% in  men54. Our results show that the consumption of 
probiotics has a decreasing effect on serum cholesterol levels. The mechanisms behind this reduction are that 
probiotics seem to be able to reduce serum cholesterol levels by reducing cholesterol absorption in the  intestines55 
and by the inhibition of HMG-CoA reductase enzyme thereby inhibiting endogenous cholesterol  synthesis56.
The exact mechanism of action for the beneficial effects of probiotics on glycemia-related parameters is not 
fully elucidated. The favorable effects may be due to the immunoregulatory properties of probiotics. Cani et al. 
demonstrated, that metabolic endotoxemia dysregulates the inflammatory tone and triggers body weight gain 
and diabetes. Alterations in glucose homeostasis are associated with low-grade inflammation promoted by gut 
microbiota-derived lipopolysaccharide or endotoxin in  mice57. Therefore, lowering plasma lipopolysaccharide 
concentration could be a strategy for the control of metabolic diseases, such as diabetes mellitus. Naito et al. 
showed that oral administration of Lactobacillus casei strain to obese mice led to a better insulin resistance 
through decreasing plasma levels of lipopolysaccharide-binding protein, a marker of  endotoxemia58.
In our meta-analysis, probiotics significantly reduced total cholesterol, triglyceride levels, CRP levels, HbA1c 
levels, fasting plasma glucose levels, fasting insulin, and blood pressure together with the increase of the HDL 
levels. The observed small changes may not seem to be clinically significant, however the beneficial changes in 
many parameters can add up leading to a reduction in the severity of type 2 diabetes-related complications, and, 
Figure 3.  Forest plot for the effect of probiotics on total cholesterol (T-chol) compared to controls in pooled 
analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in 
mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates 
the pooled effect. The figure shows the summary of studies overall and subdivided by length of intervention. 
“long”: 12 weeks or longer, “short”: 8 weeks or shorter.
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as a consequence in lower mortality. The main strength of our study is that we included exclusively randomized 
clinical trials for evaluation and the number of the included trials were much higher than in other meta-analyses 
in this field. Some of our outcomes (triglyceride levels, systolic and diastolic blood pressure values) included 
a homogenous data set, so confounding factors are unlikely to distort our results. Waist to hip ratio was not 
measured in most of the articles, so that we could not pool the data.
We attempted to determine whether the observed heterogeneity in our outcomes was due to the differences 
in the length of treatment or in the number of probiotics used. However, according to our subgroup analyses 
high heterogeneity still remained unknown. We need more randomized clinical trials to be able to determine 
the most beneficial bacteria, the optimal dosage and treatment period. The identified significant heterogeneity 
is due to the significant differences between the intervention of the selected articles.
There are considerable limitations in our study. The diversified settings made it impossible to assess the effect 
of specific probiotic strains on the analyzed parameters. Many of the analyzed studies used probiotic mixtures or 
dairy products containing several probiotic strains. The data of diversity and richness of gut microbiota are absent 
in some of the included studies. The number of the probiotic species used in the included trials varied between 
the studies included in the analysis. The duration of probiotic intervention differed between the included trials. 
Consequently, substantial heterogeneity was observed between trials within this meta-analysis. No subgroup 
analysis was possible to assess which particular probiotic preparation could be the most effective to improve 
metabolic parameters in diabetic patients. Differences in population or differences in outcome were not consider-
able. The study aim was to test different cardiometabolic parameters in patients with diabetes mellitus type 2 in 
all included studies. However, differences in intervention were substantial, due to the fact, that different species 
Figure 4.  Forest plot for the effect of probiotics on total cholesterol (T-chol) compared to controls in pooled 
analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference in 
mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates 
the pooled effect. The figure shows the summary of studies overall and subdivided by the number of bacterial 
species used. “multiple”: combination of bacteria, “single”: one bacterial species used.
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or different probiotic combinations were used. This fact is worth to mention, because we are not able to have 
high quality evidence due to the very high indirectness.
In conclusion, according to our meta-analysis the administration of probiotics has a beneficial role in the 
management of type 2 diabetes regarding metabolic profile. We have shown a significant effect of probiotics in 
reducing total cholesterol, triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels and 
both systolic and diastolic blood pressure values. Supplementation with probiotics increased HDL level and it 
did not had a significant effect on BMI or LDL levels. The practical implication of our study is that probiotic 
administration as a supportive intervention of type 2 diabetes could be incorporated into diabetes guidelines to 
beneficially modify cardiometabolic risk factors. Further studies are needed to investigate the combined effects 
of the different antidiabetic drugs and probiotic species.
Figure 5.  Forest plot for the effect of probiotics on fasting plasma glucose (FPG) compared to controls in 
pooled analysis. The shaded diamonds indicate the effect of probiotics in a particular study (weighted difference 
in mean). The horizontal lines represent 95% confidence intervals (CIs). The big diamond data marker indicates 
the pooled effect. The figure shows the summary of studies overall and subdivided by length of intervention. 
“long”: 12 weeks or longer, “short”: 8 weeks or shorter.
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